Alfonso Sabater
Cornea and External Diseases Specialist · Miami, FLNPI 1760841704
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. GSK accounts for 63.7% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $25,345 and has fallen 68.6% since, to $7,968 in 2025.
Across 89 payments — averaging $448.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$25K
- Recordati_rare_diseases_inc.$4K
- Bausch & Lomb Americas Inc.$3K
- AstraZeneca$2K
- AbbVie$1K
- Krystal Biotech Inc$1K
- plus $4K from 16 others
Across 4 payments — averaging $1041.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Recordati_rare_diseases_inc.$4K
What the payments were for
- Consulting fees$20,65152%
- Speaking & faculty fees$14,00035%
- Food & beverage$5,29613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $25,460 |
| Recordati_rare_diseases_inc. | 1 | $4,165 |
| Bausch & Lomb Americas Inc. | 6 | $2,549 |
| AstraZeneca | 1 | $1,611 |
| AbbVie(2 entities) | 5 | $1,142 |
| Krystal Biotech Inc | 1 | $1,100 |
| Dompe US, Inc. | 6 | $590 |
| Mallinckrodt Hospital Products Inc. | 17 | $580 |
| Quidel Corporation | 4 | $416 |
| Harrow Eye, LLC | 4 | $318 |
| Sun Pharmaceutical Industries Inc. | 4 | $282 |
| Biotissue Holdings Inc. | 5 | $272 |
| Novartis | 4 | $236 |
| Glaukos Corporation | 1 | $218 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $204 |
| Tarsus Pharmaceuticals, Inc. | 2 | $162 |
| Oyster Point Pharma, Inc. | 2 | $156 |
| Alcon | 3 | $153 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $130 |
| Ortho-clinical Diagnostics, Inc. | 1 | $123 |
| Thea Pharma Inc. | 1 | $57 |
| Santen Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BLENREP$16,178
- Eye Health$472
- Oxervate$365
- STELLARIS$274
- ACTHAR$248
- InflammaDry$246
- Photrexa Viscous and Photrexa$218
- KXL System$218
- VEVYE$150
- TYRVAYA$142
- IC-8 Apthera IOL$138
- CEQUA$119
- Prokera$119
- AmnioGraft$119
- Tecnis Toric 1-piece IOL$117
- Clareon$112
- XIIDRA$108
- MIEBO$102
How this compares
Too few cornea and external diseases specialist providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 92 | $63,201 |
| RestasisCyclosporine | 46 | $34,601 |
| MieboPerfluorohexyloctane/Pf | 45 | $34,141 |
| EysuvisLoteprednol Etabonate | 24 | $11,988 |
| TyrvayaVarenicline Tartrate | 14 | $9,344 |
| Prednisolone Acetate | 213 | $7,743 |
| Loteprednol Etabonate | 37 | $5,841 |
| Difluprednate | 25 | $4,174 |
| MoxifloxacinMoxifloxacin Hcl | 121 | $3,192 |
| Cyclosporine | 21 | $3,063 |
| Ketorolac Tromethamine | 74 | $1,558 |
| Doxycycline Hyclate | 28 | $1,420 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $520 |
| ValacyclovirValacyclovir Hcl | 11 | $428 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $2,549 | $97,342137 claims |
| AbbVieRestasis | $1,142 | $34,60146 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $156 | $9,34414 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $204 | $5,84137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Miami
- Benny WongMiami$2K
- Francesco Pozzo GiuffridaMiami$951
- Priya MathewsVenice$358K
- Mark HerschelWinter Park$6K
- Leslie GarayOrlando$5K
- Ana Maria OlivaBrandon$5K
- Ansuya DeosaranBoynton Beach$3K
- Malka KirschenbaumBoynton Beach$3K
- Samantha HabhabJacksonville$3K
- Neha ShaikPalm Beach Gardens$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.